The West Africa Competitiveness Programme (WACOMP) has impacted the competitiveness of 48,849 Small and Medium-sized ...

Cassava Sciences' stock rose 9% after completing ... since in practice it only has two products, one of which may have the capacity to revolutionize the treatment of Alzheimer's, but phase 3 ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

The Senior Special Adviser to the President on Industrialisation at the African Development Bank, Prof. Banji ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

That was a far steeper fall than the 0.2% sag of the S&P 500 index on the day. Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission ...

WASHINGTON, Sept 26 (Reuters) - Shares of Cassava Sciences (SAVA.O), opens new tab fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the ...

Cassava faces a cash burn of $80-$90 million in the second half of 2024, which will significantly reduce its current cash runway. Due to data integrity issues and unproven efficacy, I maintain a ...

Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

Cassava Sciences (NASDAQ: SAVA) ended the week with a piece of dispiriting news. It's going to reach deep into its coffers to settle charges brought by the most important financial-markets ...